ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Suptavumab Does Not Meet Primary Endpoint
americanpharmaceuticalreview
August 15, 2017Regeneron Pharmaceuticals announced a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of preventing medically-attended RSV infections in infants.
Pharma Sources Insight January 2025
